CareDx (CDNA) Q1 2026 Earnings Call Transcript
Image source: The Motley Fool.
Tuesday, April 28, 2026 at 4:30 p.m. ET
(NASDAQ:CDNA) announced the divestiture of its Lab Products business for $170 million upfront, expected to close by the third quarter and streamline focus on precision diagnostics and digital patient solutions. Management disclosed the acquisition of Navaris, an HPV-driven solid-tumor diagnostics provider with established commercial operations, adding a proprietary, ADLT-designated test and $34 million estimated 2025 revenue with 30%-40% annual growth potential. Full-year 2026 guidance for revenue and adjusted EBITDA was raised to reflect continued strong momentum, with higher expectations for testing service revenues and digital solution adoption across integrated healthcare systems. No financial contribution from Navaris is included in current 2026 guidance, and the Lab Products financial carve-out details were presented for investor modeling following the expected transaction close. Management emphasized sequential pipeline execution, expansion into MRD and multi-indication oncology testing, and ongoing efforts to further integrate and automate workflows for clinical partners to support margin optimization and volume growth.
Source Fool.com
